Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Caris Life Sciences to present CapeAI study predicting capecitabine response in ER+ breast cancer at ESMO 2026

By Public Technologies
  • Caris Life Sciences flagged eight AI-driven precision-oncology studies slated for presentation at the ESMO Congress 2026 in Madrid.
  • Results have not yet been presented; posters are scheduled for Oct. 23–27, 2026, with Caris-led sessions on Oct. 25.
  • Two Caris-led studies aim to improve breast-cancer treatment selection by predicting capecitabine response, risk, and endocrine-therapy benefit stratification.
  • Collaborative posters extend the approach to lung cancer, endometrial cancer, melanoma, and immuno-oncology to support biomarker discovery and therapy-response prediction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610140830PR_NEWS_USPR_____DA71516) on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.